Expert Review of Anticancer Therapy最新文献

Contemporary management of advanced gastric and gastroesophageal adenocarcinomas.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-08 DOI: 10.1080/14737140.2025.2463493

Jane E Rogers, Jaffer A Ajani

{"title":"Contemporary management of advanced gastric and gastroesophageal adenocarcinomas.","authors":"Jane E Rogers, Jaffer A Ajani","doi":"10.1080/14737140.2025.2463493","DOIUrl":"10.1080/14737140.2025.2463493","url":null,"abstract":"Introduction: Gastric and gastroesophageal adenocarcinomas (GEACs) continue to carry a poor prognosis in most patients. New and exciting therapies have entered the treatment landscape in recent years. Prior to these recent approvals, treatment advances had been limited.Areas covered: Important treatment decision biomarkers for metastatic GEAC are microsatellite instability-high/deficient mismatch repair, human epidermal growth factor receptor-2, programmed-death ligand 1, and claudin 18.2 expression among others (such as Epstein Barr Virus (EBV) and agnostic biomarkers). Results of these biomarkers drive therapy decisions. Second-line treatment in most cases is less biomarker driven and needs further progress.Expert opinion: Studies of molecular subsets in GEAC has led to the understanding that these are heterogenous diseases that need to be treated differently. Other biomarkers with targeted therapies are being studied including fibroblast growth factor receptor, trophoblast cell surface antigen-2, and epidermal growth factor receptor. Additionally, epidemiological distinctions are starting to drive therapy such as in EBV in GAC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FLT3-mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-07 DOI: 10.1080/14737140.2025.2461632

Mohamed J Saadh, Waleed K Abdulsahib, Dilfuza Ashurova, Gaurav Sanghvi, Suhas Ballal, Rsk Sharma, Piyus Kumar Pathak, Shankhyan Aman, Abhinav Kumar, Fadhil Feez Sead, M V N L Chaitanya

{"title":"FLT3-mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape.","authors":"Mohamed J Saadh, Waleed K Abdulsahib, Dilfuza Ashurova, Gaurav Sanghvi, Suhas Ballal, Rsk Sharma, Piyus Kumar Pathak, Shankhyan Aman, Abhinav Kumar, Fadhil Feez Sead, M V N L Chaitanya","doi":"10.1080/14737140.2025.2461632","DOIUrl":"10.1080/14737140.2025.2461632","url":null,"abstract":"Introduction: Acute Myeloid Leukemia is a heterogeneous hematological malignancy characterized by the uncontrolled proliferation of abnormal myeloid cells. Besides several other genetic abnormalities developed in AML, FLT3 mutations are significant due to their worse prognostic impacts and therapeutic resistance. As a result, these mutations enable AML cells to develop mechanisms for evading immune surveillance.Areas covered: This review discusses the ways of immune escape of FLT3-mutated AML cells. A literature search was conducted on PubMed, Scopus, and Web of Science databases, covering articles published between 2010 and 2024 with related keywords. The discussion covers AML cells' downregulation of immune recognition markers, expression of immune checkpoint proteins, and establishment of an immunosuppressive tumor microenvironment. Specific attention is given to small extracellular vesicles and their participation in immune escape. The focus is on exosome-mediated pathways and possible combination therapies.Expert opinion: FLT3 mutations in AML represent a formidable therapeutic challenge due to their crucial role in immune evasion. Exosomes are major players in these processes. Combination therapies targeting the exosome pathway could significantly improve these patients' immune recognition and overall outcomes. Understanding the underlying mechanisms, including targeted therapies, will be required to transcend existing therapeutic limitations and push newer strategies in treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-07 DOI: 10.1080/14737140.2025.2464208

Yuxuan Lin, Yonghe Liao, Jinhai Shen

{"title":"Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence.","authors":"Yuxuan Lin, Yonghe Liao, Jinhai Shen","doi":"10.1080/14737140.2025.2464208","DOIUrl":"10.1080/14737140.2025.2464208","url":null,"abstract":"Background: The role of angiotensin system inhibitors (ASIs) in modifying the prognosis for patients undergoing pancreatic cancer resection is not yet definitively established. This meta-analysis endeavors to consolidate existing real-world data to provide a robust, evidence-based assessment of their impact on clinical outcomes.Methods: A meticulous search strategy was devised and executed across PubMed, Embase, and Web of Science databases to retrieve all relevant studies evaluating the prognostic impact of ASIs in patients who have undergone resection for pancreatic cancer. Studies comparing survival outcomes between ASI users and non-users were included in the meta-analysis. Publication bias was assessed using funnel plotand Egger's test. Sensitivity analysis employing the leave-one-out approach was conducted to ensure the robustness and reliability of the pooled estimate.Results: Seven studies encompassing 8,549 patients were analyzed. The utilization of ASIs was significantly associated with improved overall survival (HR: 0.78; 95%CI: 0.68-0.89) in patients undergoing pancreatic cancer resection. Sensitivity analysis further validated the consistency and stability of the pooled result.Conclusion: Current clinical evidence suggests that ASIs are associated with improved prognosis in patients who have undergone pancreatic cancer resection. These findings highlight the potential of ASIs as a beneficial adjunctive therapy in the management of resected pancreatic cancer, warranting their consideration in clinical management protocols.Registration: PROSPERO (identifier: CRD42024580624).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nomograms for predicting overall and Cancer-specific Survival among patients with prostatic ductal adenocarcinoma: a population-base study.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-07 DOI: 10.1080/14737140.2025.2464926

Zhan Zhao, QianSan Zhu

{"title":"Nomograms for predicting overall and Cancer-specific Survival among patients with prostatic ductal adenocarcinoma: a population-base study.","authors":"Zhan Zhao, QianSan Zhu","doi":"10.1080/14737140.2025.2464926","DOIUrl":"https://doi.org/10.1080/14737140.2025.2464926","url":null,"abstract":"Background: Prostatic ductal adenocarcinoma (PDA) is a rare malignant tumor, and research on its clinical features and prognosis is scarce. This study aims to develop prognostic nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) in patients with PDA.Research design and methods: Among the 1,049 identified patients, an 8:2 random division yielded development and validation cohorts. Univariate and multivariate Cox analyses were performed to identify independent prognostic factors, which were then incorporated into nomograms predicting 1-, 3-, and 5-year OS and CSS for patients with PDA. The prognostic nomograms were evaluated using Concordance index (C-index) and receiver operating characteristic (ROC) curve, with internal validation performed through Decision Curve Analysis (DCA).Results: Independent prognostic factors, including age, marital status, lymph node status, distant metastasis, surgery method, chemotherapy, and Gleason score, were incorporated into the developed nomograms. The results of training (C-index: OS = 0.74, CSS = 0.69; AUC value: OS = 0.822-0.892, CSS = 0.836-0.873) and internal validation (C-index: OS = 0.78, CSS = 0.77) indicated our nomograms had good performance The clinical decision curve indicated that the nomogram had a good clinical net benefit.Conclusions: This study successfully established and validated prognostic nomograms tailored for PDA patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in immunotherapy for hepatocellular carcinoma.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-06 DOI: 10.1080/14737140.2025.2461631

Sara Ascari, Rusi Chen, Caterina Vivaldi, Bernardo Stefanini, Andrea De Sinno, Andrea Dalbeni, Piera Federico, Francesco Tovoli

{"title":"Advancements in immunotherapy for hepatocellular carcinoma.","authors":"Sara Ascari, Rusi Chen, Caterina Vivaldi, Bernardo Stefanini, Andrea De Sinno, Andrea Dalbeni, Piera Federico, Francesco Tovoli","doi":"10.1080/14737140.2025.2461631","DOIUrl":"10.1080/14737140.2025.2461631","url":null,"abstract":"Introduction: The advent of immune-based combinations, primarily leveraging immune checkpoint inhibitors, has revolutionized the therapeutic landscape of hepatocellular carcinoma (HCC). The current scenario features multiple therapies that have shown superiority over tyrosine kinase inhibitors; however, the absence of direct comparisons and validated prognostic biomarkers complicates therapeutic decision-making. Additionally, a significant proportion of patients still exhibit primary or secondary resistance to existing immunotherapies, underscoring the ongoing need for novel therapeutic strategies.Areas covered: This narrative review discusses current strategies aimed at improving the efficacy of immunotherapy for HCC, focusing on the following aspects: available therapeutic options, identification of prognostic biomarkers, approaches to overcoming resistance (including the development of neoantigen vaccines), and the exploration of adjuvant and neoadjuvant strategies.Expert opinion: The future of systemic therapies for HCC is likely to be driven by advancements in immunotherapy. Key areas of exploration for the coming years include the discovery of novel checkpoint inhibitors or complementary agents to enhance tumor response when combined with existing treatments, a shift toward neoadjuvant/perioperative trials instead of traditional adjuvant approaches, and the development of personalized neoantigen vaccines.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence. 肾素-血管紧张素系统抑制剂对卵巢癌患者预后的影响：真实世界证据的荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-06 DOI: 10.1080/14737140.2025.2463486

Pian Wang, Xinmiao Zhang, Jinhai Shen

{"title":"Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence.","authors":"Pian Wang, Xinmiao Zhang, Jinhai Shen","doi":"10.1080/14737140.2025.2463486","DOIUrl":"10.1080/14737140.2025.2463486","url":null,"abstract":"Background: The prognostic impact of renin-angiotensin system inhibitors (RASIs) on ovarian cancer (OC) remains indeterminate. This meta-analysis aims to consolidate real-world data to provide a comprehensive, evidence-based assessment of the association between RASIs use and clinical outcomes in OC patients.Methods: A meticulous search strategy was devised and executed across PubMed, Scopus, and Embase databases to retrieve all relevant studies evaluating the prognostic impact of RASIs in patients with OC. Studies comparing survival outcomes between RASIs users and non-users were included in the meta-analysis.Results: A total of six studies, encompassing 11 cohorts and 14,634 patients, were included in the meta-analysis. RASIs use was found to be significantly correlated with enhanced survival (HR: 0.82; 95%CI: 0.72-0.92) in the OC patient population. Subgroup analysis showed that ACEIs use (HR: 0.83, 95% CI: 0.78-0.89) and post-diagnostic RASIs use (HR: 0.77, 95% CI: 0.66-0.90) significantly improved overall survival.Conclusion: This meta-analysis provides evidence that RASIs are associated with improved prognosis in OC patients. These findings suggest that RASIs may have potential as an adjunctive therapy in the management of OC, warranting further investigation and consideration in clinical management protocols.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The discordance of biomarkers in primary tumor and synchronous axillary lymph node metastasis of the breast cancer, and its clinical significance in patients undergoing neoadjuvant therapy.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-06 DOI: 10.1080/14737140.2025.2464199

Ali Kaan Sanal, Umit Turan, Ahmet Yugruk, Zeynel Abidin Taş, Oktay Irkorucu, Omer Taskin

{"title":"The discordance of biomarkers in primary tumor and synchronous axillary lymph node metastasis of the breast cancer, and its clinical significance in patients undergoing neoadjuvant therapy.","authors":"Ali Kaan Sanal, Umit Turan, Ahmet Yugruk, Zeynel Abidin Taş, Oktay Irkorucu, Omer Taskin","doi":"10.1080/14737140.2025.2464199","DOIUrl":"https://doi.org/10.1080/14737140.2025.2464199","url":null,"abstract":"Background: This study explores the disparity in ER, PR, HER-2, and Ki-67 status between primary breast tumors (PBT) and axillary lymph node metastasis (ALNM) at initial admission in patients undergoing neoadjuvant chemotherapy (NAC).Research design and methods: Demographic-clinicopathological characteristics and histopathological response to NAC in both PBT and ALNM were recorded. Immunohistochemical analysis of ER, PR, HER-2, and Ki67 was performed separately in PBT and ALNM, with discordance rates compared. The disparity in biomarkers was assessed in relation to the histopathological response to NAC in both PBT and ALNM.Results: In 96 female patients, discordance rates between PBT and ALNM were 16.67% for ER, 16.67% for PR, 20.83% for HER-2, and 15.63% for Ki-67. Statistically significant differences in ER and PR discordance between PBT and ALNM were observed. Additionally, a significant difference in histopathological response to NAC was noted based on ER discordance.Conclusion: Precise assessment of ER and HER-2 status in axillary lymph node biopsy specimens is crucial in breast cancer patients with ALNM, potentially optimizing systemic and surgical treatment selection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities in Consent to Adjuvant Radiotherapy in Primary Glioblastoma: a population-based study.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-06 DOI: 10.1080/14737140.2025.2464935

Miao Wang, Yang Liu, Jinhu Li, Xia Yan, Ying Lu, Xin Yang

{"title":"Disparities in Consent to Adjuvant Radiotherapy in Primary Glioblastoma: a population-based study.","authors":"Miao Wang, Yang Liu, Jinhu Li, Xia Yan, Ying Lu, Xin Yang","doi":"10.1080/14737140.2025.2464935","DOIUrl":"https://doi.org/10.1080/14737140.2025.2464935","url":null,"abstract":"Background: Despite adjuvant external beam radiation therapy (EBRT) has long been the standard treatment for glioblastoma (GBM), a significant subset of patients chooses to refuse it. We aimed to investigate the factors influencing EBRT refusal in GBM.Research design and methods: Patients with GBM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Both univariable and multivariable logistic regression analyses were employed to evaluate the adjusted odds ratios (aOR) for the refusal of EBRT in relation to various clinical and demographic characteristics.Results: Among the 29,994 patients analyzed, 675 (2.3%) opted to refuse adjuvant EBRT. Patients aged ≥55 years (55-64: aOR 1.63, 95% CI 1.04-2.61, p = 0.03; 65-74: aOR 1.80, 95% CI 1.17-2.87, p = 0.009; 75+: aOR 2.01, 95% CI 1.28-3.24, p = 0.002), being single (aOR 1.68, 95% CI 1.19-2.35, p = 0.002), with a household income of $55,000 to $64,999 (aOR 1.94, 95% CI 1.24-3.07, p = 0.004), and not undergoing chemotherapy (aOR 114, 95% CI 80.2-170.2, p < 0.001) had significantly higher odds of refusing adjuvant EBRT.Conclusions: This study underscores the necessity for targeted communication strategies by physicians regarding the benefits of adjuvant EBRT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-03 DOI: 10.1080/14737140.2025.2460537

Aws Khalid Abushanab, Mus'ab Theeb Mustafa, Mahmoud Taysir Mousa, Renad Fawwaz Albanawi, Razan Mohammad Alkhalaileh, Ghaith Nahar Alqudah, Razan Feras Abu Zaina, Zaina Ammar Abu Sitta, Issa Mohammad Almasri, Dua Abuquteish

{"title":"Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels.","authors":"Aws Khalid Abushanab, Mus'ab Theeb Mustafa, Mahmoud Taysir Mousa, Renad Fawwaz Albanawi, Razan Mohammad Alkhalaileh, Ghaith Nahar Alqudah, Razan Feras Abu Zaina, Zaina Ammar Abu Sitta, Issa Mohammad Almasri, Dua Abuquteish","doi":"10.1080/14737140.2025.2460537","DOIUrl":"10.1080/14737140.2025.2460537","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) are currently the primary approach for managing NSCLC. However, numerous combination therapies are currently under investigation. Our goal is to investigate the overall efficacy and safety of ICIs and taxane-based chemotherapy.Methods: We conducted a systematic review and meta-analysis, searching web databases for relevant literature. We limited our eligibility to phase II/III randomized clinical trials involving advanced/metastatic NSCLC patients.Results: We performed a meta-analysis encompassing nineteen studies derived from sixteen RCTs. For patients with sq-NSCLC PD-L1 ≥ 50%, using ICIs plus taxane significantly improve PFS and OS with HR of 0.58 (95% CI, 0.45-0.74, p < 0.0001) and 0.41 (95% CI, 0.33-0.50, p < 0.00001), respectively. For patients with non-sq NSCLC PD-L1 1-49%, the analysis revealed significant improvement of OS and PFS with HR of 0.64 (95% CI, 0.47-0.88, p = 0.005) and 0.62 (95% CI, 0.47-0.81, p = 0.0004), respectively. For TRAEs of all grades, ICIs plus taxane resulted with no significant difference compared to control group with risk ratio (RR) 1.00 (95% CI 0.99-1.02).Conclusion: The analysis revealed significant improvement in efficacy of ICIs with taxane in advanced/metastatic NSCLC patients compared with ICI/taxane monotherapy.Registration: PROSPERO (CRD42023447532).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.9,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-29 DOI: 10.1080/14737140.2025.2458156

Ekta Shirbhate, Vaibhav Singh, Rakesh Kore, Biplab Koch, Ravichandran Veerasamy, Amit Kumar Tiwari, Harish Rajak

{"title":"Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy.","authors":"Ekta Shirbhate, Vaibhav Singh, Rakesh Kore, Biplab Koch, Ravichandran Veerasamy, Amit Kumar Tiwari, Harish Rajak","doi":"10.1080/14737140.2025.2458156","DOIUrl":"10.1080/14737140.2025.2458156","url":null,"abstract":"Introduction: The synergistic combination of histone deacetylase inhibitors and platinum-based medicines represents a promising therapeutic strategy to efficacy and overcome drug resistance in cancer therapy, necessitating a comprehensive understanding on their molecular interactions and clinical potential.Areas covered: The objective of presented review is to investigate the molecular pathways of platinum medicines and HDAC inhibitors. A comprehensive literature review from 2011 to 2024 was conducted across multiple databases like MEDLINE, PubMed, Google Scholar, Science Direct, Scopus and official websites of ClinicalTrial.gov to explore publications on HDAC inhibitors, platinum drugs, and combination cancer therapies, revealing preliminary evidence of innovative treatment strategies involving HDAC inhibitors and platinum chemotherapeutics. Several new platinum (IV) complexes, with HDAC inhibitory moieties and better cytotoxicity profiles than conventional platinum drugs, are also reviewed here.Expert opinion: The above combination has great potential in cancer treatment, however managing toxicity, dosage regimens, and patient selection biomarkers are problematic. More selective HDAC inhibitors and innovative delivery techniques are potential areas for future research. An adaptation toward changing cancer therapeutic landscapes, highlights combining HDAC inhibitors with platinum-based medicines serves as a new concept for personalized medicine, however, a deeper research is still needed at this time.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-21"},"PeriodicalIF":2.9,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0